Return to homepagePandemic Pact

DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93023C00051-0-9999-1

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2023
    2025

  • Known Financial Commitments (USD)

    $3,692,037

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    GREG HENKEL

  • Research Location

    United States of America

  • Lead Research Institution

    ARISAN THERAPEUTICS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

To support the advanced development of a promising candidate therapeutic for a virus with pandemic potential included under the Antiviral Program for Pandemics. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.